Empagliflozin + Linagliptin

Category: Diabetes



Empagliflozin + Linagliptin Overview

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a drug combination used for the treatment of type 2 diabetes. It is a combination of empagliflozin and linagliptin. It was approved for use in the United States in January 2015.[4][5] History The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi. References ^ a b "Empagliflozin / linagliptin (Glyxambi) Us...

Read more Empagliflozin + Linagliptin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Empagliflozin/linagliptin

Recent Empagliflozin + Linagliptin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Empagliflozin + Linagliptin
  • Tablet: 10mg + 5mg, 25mg + 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (12 results)

Related Empagliflozin + Linagliptin Topics:

trajenta linagliptin
what is deference between istamet and trajenta and side effects...




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 31 March 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA